|Authors||Downs TM, Schultzel M, Shi H, Sanders C, Tahir Z, Sadler GR|
|Journal||Crit. Rev. Oncol. Hematol. Volume: 70 Issue: 1 Pages: 59-70|
|Publish Date||2009 Apr|
Surgical management of renal cell carcinoma is the most effective treatment for patients with localized disease. In patients with advanced renal cell carcinoma, immune modulation-based therapies are typically used to improve cancer-specific survival. Similar to most cancers, tumor grade and stage are linked to the tumor’s biologic potential. Integrating these factors with patients’ performance status can help predict their long-term disease-free survival, the likelihood of tumor recurrence, and the median time to failure following surgery and immunotherapy. A novel integrated staging system and a postoperative renal cell carcinoma specific nomogram, along with standardized quality of life assessments have been shown to be useful clinical tools to aid in patient counseling, determining optimal follow-up imaging protocols, and identifying patients who might benefit from early enrollment in adjuvant therapy protocols. This article offers clinicians a review and summary of the most recent evidence-based research related to risk assessment among patients with newly diagnosed renal cell carcinoma.
|Full Text||Full text available on PubMed Central|